Therapy of Treatment Failure After Curative Treatment of Prostate Cancer

EAU-EBU Update Series

Volumn 4, Issue 6, 2006, Pages 228-240

  Schwarz, Rudolf ^a   Graefen, Markus ^b   Krüll, Andreas ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Martini Clinic Prostate Cancer Center   (Germany)

Author keywords

Biochemical failure; Brachytheray; Cryotherapy; Prostate cancer; PSA; Radiotherapy; Salvage; Salvage prostatectomy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; HORMONE; IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

BRACHYTHERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CRYOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HEMATURIA; HEMORRHAGIC CYSTITIS; HUMAN; METASTASIS; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RECTUM HEMORRHAGE; RECTUM ULCER; RECURRENCE RISK; RECURRENT CANCER; REVIEW; SALVAGE THERAPY; SURGICAL TECHNIQUE; TREATMENT FAILURE; URETHRA STRICTURE; UROGENITAL TRACT DISEASE;

EID: 33750481219     PISSN: 18712592     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eeus.2006.08.001     Document Type: Review

References (109)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Moul J.W. Prostate specific antigen only progression of prostate cancer. J Urol 163 (2000) 1632-1642
3. Lee W.R., Hanks G.E., and Hanlon A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol 15 (1997) 230-238
4. D'Amico A.V., Cote K., Loffredo M., Renshaw A.A., and Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20 (2002) 4567-4573
5. Pinover W.H., Horwitz E.M., Hanlon A.L., Uzzo R.G., and Hanks G.E. Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Cancer 97 (2003) 1127-1133
6. Touma N.J., Izawa J.I., and Chin J.L. Current status of local salvage therapies following radiation failure for prostate cancer. J Urol 173 (2005) 373-379
7. Stephenson A.J., and Eastham J.A. Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol 23 (2005) 198-203
8. Zelefsky M.J., Leibel S.A., Kutcher G.J., Kelson S., Ling C.C., and Fuks Z. The Feasibility of Dose Escalation with Three-Dimensional Conformal Radiotherapy in Patients with Prostatic Carcinoma. Cancer J Sci Am 1 (1995) 142
9. Zagars G.K., Pollack A., and von Eschenbach A.C. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 33 (1995) 23-35
10. Holzman M., Carlton Jr. C.E., and Scardino P.T. The frequency and morbidity of local tumor recurrence after definitive radiotherapy for stage C prostate cancer. J Urol 146 (1991) 1578-1582
11. Fuks Z., Leibel S.A., Wallner K.E., Begg C.B., Fair W.R., Anderson L.L., et al. The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys 21 (1991) 537-547
12. Kaplan I.D., Prestidge B.R., Bagshaw M.A., and Cox R.S. The importance of local control in the treatment of prostatic cancer. J Urol 147 (1992) 917-921
13. Bianco Jr. F.J., Scardino P.T., Stephenson A.J., Diblasio C.J., Fearn P.A., and Eastham J.A. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 62 (2005) 448-453
14. Amling C.L., Lerner S.E., Martin S.K., Slezak J.M., Blute M.L., and Zincke H. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol 161 (1999) 857-862
15. Izawa J.I., Ajam K., McGuire E., Scott S., von Eschenbach A.C., Skibber J., et al. Major surgery to manage definitively severe complications of salvage cryotherapy for prostate cancer. J Urol 164 (2000) 1978-1981
16. Rogers E., Ohori M., Kassabian V.S., Wheeler T.M., and Scardino P.T. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol 153 (1995) 104-110
17. Gheiler E.L., Tefilli M.V., Tiguert R., Grignon D., Cher M.L., Sakr W., et al. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology 51 (1998) 789-795
18. 125I implantation. Br J Urol 75 (1995) 44-47
19. Link P., and Freiha F.S. Radical prostatectomy after definitive radiation therapy for prostate cancer. Urology 37 (1991) 189-192
20. Moul J.W., and Paulson D.F. The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. Cancer 68 (1991) 1265-1271
21. Pontes J.E., Montie J., Klein E., and Huben R. Salvage surgery for radiation failure in prostate cancer. Cancer 71 (1993) 976-980
22. Stein A., Smith R.B., and deKernion J.B. Salvage radical prostatectomy after failure of curative radiotherapy for adenocarcinoma of prostate. Urology 40 (1992) 197-200
23. Cox J.D., Gallagher M.J., Hammond E.H., Kaplan R.S., and Schellhammer P.F. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 17 (1999) 1155-1163
24. Kuban D.A., Thames H.D., Levy L.B., Horwitz E.M., Kupelian P.A., Martinez A., et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 57 (2003) 915-928
25. Shipley W.U., Thames H.D., Sandler H.M., Hanks G.E., Zietman A.L., Perez C.A., et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 281 (1999) 1598-1604
26. Crook J.M., Perry G.A., Robertson S., and Esche B.A. Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology 45 (1995) 624-631 discussion 631-2
27. Scardino P.T., and Wheeler T.M. Local control of prostate cancer with radiotherapy: frequency and prognostic significance of positive results of postirradiation prostate biopsy. NCI Monogr (1988) 95-103
28. Kabalin J.N., Hodge K.K., McNeal J.E., Freiha F.S., and Stamey T.A. Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen. J Urol 142 (1989) 326-331
29. Borghede G., Aldenborg F., Wurzinger E., Johansson K.A., and Hedelin H. Analysis of the local control in lymph-node staged localized prostate cancer treated by external beam radiotherapy, assessed by digital rectal examination, serum prostate-specific antigen and biopsy. Br J Urol 80 (1997) 247-255
30. Crook J., Malone S., Perry G., Bahadur Y., Robertson S., and Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 48 (2000) 355-367
31. Zelefsky M.J., Fuks Z., Hunt M., Lee H.J., Lombardi D., Ling C.C., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166 (2001) 876-881
32. Pollack A., Zagars G.K., Starkschall G., Antolak J.A., Lee J.J., Huang E., et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
33. Crook J., Malone S., Perry G., Bahadur Y., Robertson S., and Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 48 (2000) 355-367
34. Stephenson A.J., Scardino P.T., Bianco Jr. F.J., DiBlasio C.J., Fearn P.A., and Eastham J.A. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol (2004) 1739-1743
35. Zietman A.L., Tibbs M.K., Dallow K.C., Smith C.T., Althausen A.F., Zlotecki R.A., et al. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol 40 (1996) 159-162
36. Critz F.A., Williams W.H., Holladay C.T., Levinson A.K., Benton J.B., Holladay D.A., et al. Post-treatment PSA < or = 0.2 ng/ml defines disease freedom after radiotherapy for prostate cancer using modern techniques. Urology 54 (1999) 968-971
37. Sartor C.I., Strawderman M.H., Lin X.H., Kish K.E., McLaughlin P.W., and Sandler H.M. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 38 (1997) 941-947
38. Ward J.F., Sebo T.J., Blute M.L., and Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol 173 (2005) 1156-1160
39. Lerner S.E., Blute M.L., and Zincke H. Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. J Urol 154 (1995) 1103-1109
40. Perrotte P., Litwin M.S., McGuire E.J., Scott S.M., von Eschenbach A.C., and Pisters L.L. Quality of life after salvage cryotherapy: the impact of treatment parameters. J Urol 162 (1999) 398-402
41. Chin J.L., Pautler S.E., Mouraviev V., Touma N., Moore K., and Downey D.B. Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. J Urol 165 (2001) 1937-1941 discussion 1941-2
42. Ghafar M.A., Johnson C.W., De La Taille A., et al. Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience. J Urol 166 (2001) 1333-1337 discussion 1337-8
43. Beyer D.C. Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology 54 (1999) 880-883
44. Grado G.L., Collins J.M., Kriegshauser J.S., et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 53 (1999) 2-10
45. Catalona W.J., and Smith D.S. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 152 (1994) 1837-1842
46. Kupelian P.A., Katccher J., Levin H.S., and Klein E.A. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Rad Oncol Biol Phys 37 (1997) 1043-1052
47. Anscher M.S., Clough R., and Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first ten years. Int J Radiat Oncol Biol Phys 48 (2000) 369-375
48. Cadeddu J.A., Partin A.W., De Weese T.L., and Walsh P.C. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 159 (1998) 173-177
49. Nudell D.M., Grossfeld G.D., Weinberg V.K., Roach III M., and Carroll P.R. Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. Urology 54 (1999) 1049-1057
50. Pisansky T.M., Kozelsky T.F., Myers R.P., Hillmann D.W., Blute M.L., Buskirk S.J., et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol 163 (2000) 845-850
51. Anscher M.S., and Prosnitz L.R. Radiotherapy vs. hormonal therapy for the management of locally recurrent prostate cancer following radical prostatectomy. Int J Rad Oncol Biol Phys 17 (1989) 953-958
52. Wilder R.B., Hsiang J.Y., Ji M., Earle J.D., and de Vere White R. Preliminary results of three-dimensional conformal radiotherapy as salvage treatment for a rising prostate-specific antigen level postprostatectomy. Am J Clin Oncol 23 (2000) 176-180
53. Catton C., Gospodarowicz M., Warde P., Panzarella T., Catton P., Mclean M., et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol 59 (2001) 51-60
54. Zelefsky M.J., Aschkenasy E., and Kelsen S. Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 39 (1997) 327-333
55. Egawa S., Ohori M., Iwamura M., Kuwao S., and Baba S. Efficacy and limitations of delayed/salvage radiation therapy after radical prostatectomy. BJU Int 84 (1999) 815-820
56. Kalapurakal J.A., Huang C.F., Neriamparampil M.M., Small W.J., Pins M.R., Mittal B.B., et al. Biochemical disease-free survival following adjuvant and salvage irradiation after radical prostatectomy. Int J Radiat Oncol Biol Phys 54 (2002) 1047-1054
57. Chawla A.K., Thakral H.K., Zietman A.L., and Shipley W.U. Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: Analysis of efficacy and prognostic factors. Urology 59 (2002) 726-731
58. Choo R., Hruby G., Hong J., Bahk E., Hong E., Danjoux C., et al. (In)-Efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys 53 (2002) 269-276
59. Macdonald O.K., Schild S.E., Vora S.A., Andrews P.E., Ferrigni R.G., Novicki D.E., et al. Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy. Int J Rad Oncol Biol Phys 58 (2004) 1530-1535
60. Stephenson A.J., Shariat S.F., Zelefsky M.J., Kattan M.W., Butler E.B., Teh B.S., et al. Salvage radiotherapy for recurrent prostate cancer. JAMA 291 (2004) 1325-1332
61. Macdonald O.K., Schild S.E., Vora S.A., et al. Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy. J Urol 170 (2003) 1833-1837
62. Kaplan I.D., and Bagshaw M.A. Serum prostate-specific antigen after postprostatectomy radiotherapy. Urology 39 (1992) 401-406
63. Montie J.F. Follow-up after radical prostatectomy or radiation therapy for prostate cancer. Urol Clin North Am 21 (1994) 673-676
64. Partin A.W., Pound C.R., Clemens J.Q., Epstein J.I., and Walsh P. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 20 (1993) 713-725
65. Paulson D.F. Impact of radical prostatectomy in the management of clinically localized disease. J Urol 152 (1994) 1826-1830
66. Johnstone P.A.S., and Riffenburgh R. Yield of imaging and scintigraphy assessing biochemical failure in prostate cancer patients. Urol Oncol 3 (1997) 108-112
67. Cher M.L., Bianco Jr. F.J., Lam J.S., Davis L.P., Grignon D.J., Sakr W.A., et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 160 (1998) 1387-1391
68. Eulau S.M., Tate D.J., Stamey T.A., Bagshaw M., and Hancock S.L. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys 41 (1998) 735-740
69. Leventis A.K., Shariat S.F., Kattan M.W., Butler B., Wheeler T.M., and Slawin K.M. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 19 (2001) 1030-1039
70. Peschel R.E., Robnett T.J., Hesse D., King C.R., Ennis R.D., Schiff P.B., et al. PSA based review of adjuvant and salvage radiation therapy vs. Observation in postoperative prostate cancer patients. Int J Cancer 90 (2000) 29-36
71. Anscher M.S., and Prosnitz L.R. Radiotherapy vs. hormonal therapy for the management of locally recurrent prostate cancer following radical prostatectomy. Int J Rad Oncol Biol Phys 17 (1989) 953-958
72. Crane C.H., Rich T.A., Read P.W., Sanfilippo N.J., Gillenwater J.Y., and Kelly M.D. Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation. Int J Radiat Oncol Biol Phys 39 (1997) 681-686
73. Do T., Parker R.G., Do C., Tran L., Do L., and Dolkar D. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy. Cancer J Sci Am 4 (1998) 324-330
74. Mayer R., Pummer K., Quehenberger F., Mayer E., Fink L., and Hackl A. Postprostatectomy radiotherapy for high-risk prostate cancer. Urology 59 (2002) 732-739
75. Morris M.M., Dallow K.C., Zietman A.L., Park J., Althausen A., Heney N.M., et al. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 38 (1997) 731-736
76. Rogers R., Grossfeld G.D., Roach III M., Shinohara K., Presti J.C., and Carrol P.R. Radiation therapy for the management of biopsy proved local recurrence after radical prostatectomy. J Urol 160 (1998) 1748-1753
77. Vander Kooy M.J., Pisansky T.M., Cha S.S., and Blute M.L. Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy. Urology 49 (1997) 65-70
78. Vicini F.A., Ziaja E.L., Kestin L.L., Brabbins D.S., Stromberg J.S., Gonzalez J.A., et al. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology 54 (1999) 111-117
79. Wiegel T., Bressel M., Arps H., and Hübener K.H. Radiotherapy of local recurrence following radical prostatectomy. Strahlenther Onkol 168 (1992) 333-336
80. Schwarz R., Krüll A., Tribius S., and Alberti W. Results of three dimensional conformal radiotherapy and hormonal therapy for local recurrence after radical prostatectomy. Strahlenther Onkol 181 (2005) 442-447
81. Medini E., Medini I., Reddy P.K., and Levitt S.H. Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long term follow-up. Cancer 78 (1996) 1254-1259
82. Valicenti R.K., Gomella L.G., Ismail M., Mulholland S.G., Petersen R.O., and Corn B.W. Effect of higher radiation dose on biochemical control after radical prostatectomy for pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys 42 (1998) 501-506
83. De Merleer G., Vakaet L., de Gersem W., Villeirs G., and De Neve W. Direct segment aperture and weight optimization for Intensity-modulated radiotherapy of prostate cancer. Strahlenther Onkol 180 (2004) 136-143
84. Teh B.S., Mai W.Y., Augspurger M.E., Uhl B.M., McGary J., Dong L., et al. Intensity modulated radiation therapy (IMRT) following prostatectomy: more favorable acute genitourinary toxicity profile compared to primary IMRT for prostate cancer. Int J Rad Oncol Biol Phys 49 (2001) 465-472
85. Bastasch M.D., Teh B.S., Mai W.Y., Carpenter L.S., Lu H.H., Chiu J.K., et al. Post-nerve-sparing prostatectomy, dose-escalated intensity-modulated radiotherapy: effect on erectile function. Int J Rad Oncol Biol Phys 54 (2002) 101-106
86. Niehoff P., Kovacs G., Galalae R., Oldörp A., Kimmig B., Loch T., et al. Kombinierte Tele- und Brachytherapie beim Lokalrezidiv des Prostatakarzinoms nach radikaler Prostatektomie. Strahlenther Onkol 177 (2001) 18
87. Losa A., Nava L.D., Di Muzio N., Mangili P., Longobardi B., Rigatti P., et al. Salvage brachytherapy for local recurrence after radical prostatectomy and subsequent external beam radiotherapy. Urology 62 (2003) 1068-1072
88. Garzotto M., and Wajsman Z. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup. J Urol 159 (1998) 950-954 discussion 954-5
89. Ahlering T.E., Lieskovsky G., and Skinner D.G. Salvage surgery plus androgen deprivation for radioresistant prostatic adenocarcinoma. J Urol 147 (1992) 900-902
90. Link P., and Freiha F.S. Radical prostatectomy after definitive radiation therapy for prostate cancer. Urology 37 (1991) 189-192
91. Neerhut G.J., Wheeler T., Cantini M., and Scardino P.T. Salvage radical prostatectomy for radiorecurrent adenocarcinoma of the prostate. J Urol 140 (1988) 544-549
92. Mador D.R., Huben R.P., Wajsman Z., and Pontes J.E. Salvage surgery following radical radiotherapy for adenocarcinoma of the prostate. J Urol 133 (1985) 58-60
93. Thompson I.M., Rounder J.B., Spence C.R., and Rodriguez F.R. Salvage radical prostatectomy for adenocarcinoma of the prostate. Cancer 61 (1988) 1464-1466
94. Rainwater L.M., and Zincke H. Radical prostatectomy after radiation therapy for cancer of the prostate: feasibility and prognosis. J Urol 140 (1988) 1455-1459
95. Neerhut G.J., Wheeler T., Cantini M., and Scardino P.T. Salvage radical prostatectomy for radiorecurrent adenocarcinoma of the prostate. J Urol 140 (1988) 544-549
96. Zincke H. Radical prostatectomy and exenterative procedures for local failure after radiotherapy with curative intent: comparison of outcomes. J Urol 147 (1992) 894-899
97. Vaidya A., and Soloway M.S. Salvage radical prostatectomy for radiorecurrent prostate cancer: morbidity revisited. J Urol 164 (2000) 1998-2001
98. Vallancien G., Gupta R., Cathelineau X., Baumert H., and Rozet F. Initial results of salvage laparoscopic radical prostatectomy after radiation failure. J Urol 170 (2003) 1838-1840
99. Izawa J.I., Madsen L.T., Scott S.M., Tran J.P., McGuire E.J., von Eschenbach A.C., et al. Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol 20 (2002) 2664-2671
100. Ghafar M.A., Johnson C.W., De La Taille A., et al. Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience. J Urol 166 (2001) 1333-1337 discussion 1337-8
101. Han K.R., Cohen J.K., Miller R.J., Pantuck A.J., Freitas D.G., Cuevas C.A., et al. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol 170 (2003) 1126-1130
102. Miller Jr. R.J., Cohen J.K., Shuman B., and Merlotti L.A. Percutaneous, transperineal cryosurgery of the prostate as salvage therapy for post radiation recurrence of adenocarcinoma. Cancer 77 (1996) 1510-1514
103. Bales G.T., Williams M.J., Sinner M., Thisted R.A., and Chodak G.W. Short-term outcomes after cryosurgical ablation of the prostate in men with recurrent prostate carcinoma following radiation therapy. Urology 46 (1995) 676-680
104. Pisters L.L., Perrotte P., Scott S.M., Greene G.F., and von Eschenbach A.C. Patient selection for salvage cryotherapy for locally recurrent prostate cancer after radiation therapy. J Clin Oncol 17 (1999) 2514-2520
105. Long J.P., Fallick M.L., LaRock D.R., and Rand W. Preliminary outcomes following cryosurgical ablation of the prostate in patients with clinically localized prostate carcinoma. J Urol 159 (1998) 477-484
106. De La Taille A., Benson M.C., Bagiella E., Burchardt M., Shabrigh A., Olsson C.A., et al. Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence. BJU Int 85 (2000) 281-286
107. Haab F., Meulemans A., Boccon-Gibod L., Dauge M.C., Delmas V., Hennequin C., et al. Effect of radiation therapy after radical prostatectomy on serum prostate-specific antigen measured by an ultrasensitive assay. Urology 45 (1995) 1022-1027
108. Garg M.K., Tekyi-Mensah S., Bolton S., Velasco J., Pontes E., Wood D.P., et al. Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology 51 (1998) 998-1002
109. Leventis A.K., Shariat S.F., Kattan M.W., Butler B., Wheeler T.M., and Slawin K.M. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 19 (2001) 1030-1039